A Systematic Quick Method Development Approach to Optimize Protein Size Exclusion Chromatography

Importance of the Topic

Size exclusion chromatography (SEC) is a cornerstone technique for profiling therapeutic proteins, especially to quantify and characterize high–molecular-weight (HMW) aggregates and monomeric species under non-denaturing conditions. Robust SEC methods must minimize unwanted electrostatic and hydrophobic interactions that compromise resolution, recovery, and quantitation. A systematic rapid optimization framework reduces development time while ensuring reliable, entropically driven separations.

Goals and Overview of the Study

The primary aim was to implement a 2³ full factorial design of experiments (DoE) to identify optimal SEC conditions for monoclonal antibodies and an antibody–drug conjugate. Key objectives included:

• Screening mobile phase ionic strength, organic modifier content, and column temperature at low and high levels.
• Evaluating responses: monomer–aggregate resolution (Rs), HMW aggregate recovery (HMWs %), and monomer peak width (w_1/2).
• Demonstrating rapid method development in under two hours of instrument time.

Methodology and Instrumentation

Design of Experiment:

• Factors (±1 levels): ionic strength (0.5× vs 1× PBS), organic modifier (2 % vs 10 % MeOH), temperature (25 °C vs 35 °C).
• Responses: Rs between monomer and HMWs, HMWs %, and monomer peak width.
• Data analysis via linear models (first-order) and optional interaction terms, calculated in a spreadsheet.

Sample Preparation and Conditions:

• Analytes: Rituximab, trastuzumab emtansine, and bevacizumab at 1 mg/mL in water.
• Injection: 1 µL, flow rate initially 0.3 mL/min, column temperature per DoE.

Instrumentation:

• LC System: Waters ACQUITY H-Class Bio Plus quaternary pump.
• Column: XBridge Premier Protein SEC, 4.6×150 mm, 2.5 µm, 250 Å.
• Detection: UV at 280 nm; sample temperature 8 °C.

Main Results and Discussion

Pareto analysis consistently identified mobile phase ionic strength as the dominant factor influencing HMW recovery, resolution, and peak shape. Organic modifier and temperature had secondary effects on peak width and tailing. Optimal conditions (1× PBS, no organic modifier, 35 °C) maximized HMWs % recovery and produced sharp, symmetrical peaks. Verification at the DoE center point predicted HMWs % within 1 % error. Accelerated separations at 0.7 mL/min maintained adequate resolution, reducing run time to under 4 minutes per sample.

Benefits and Practical Applications of the Method

• Rapid optimization with only eight runs and < 2 hours of instrument time.
• Straightforward spreadsheet modeling avoids specialized software.
• Applicability to diverse protein therapeutics for routine QC and formulation screening.

Future Trends and Opportunities

Advances in low-adsorption stationary phases and integration with automated DoE platforms will further accelerate SEC method development. Machine-learning models trained on DoE datasets may predict optimal conditions for new biomolecules. Coupling rapid SEC with online multi-angle light scattering and mass spectrometry will enhance aggregate characterization in a single workflow.

Conclusion

A simple 2³ factorial approach enables efficient, systematic development of protein SEC methods. By focusing on ionic strength, organic modifier, and temperature, secondary interactions are identified and mitigated. The spreadsheet-based linear model accurately predicts performance across the factor space, yielding robust separations in minimal time.

Reference

1. Hong P, Koza S, Bouvier ESP. Size Exclusion Chromatography for the Analysis of Protein Biotherapeutics and Their Aggregates. J Liq Chromatogr Relat Technol. 2012;35:2923–2950.
2. Fekete S, Kizekai L, Sarisozen YT, Lawrence N, Shiner S, Lauber M. Investigating the Secondary Interactions of Packing Materials for Size‐Exclusion Chromatography of Therapeutic Proteins. J Chromatogr A. 2022;1676:463262.
3. Fekete S, Beck A, Veuthey J-L, Guillarme D. Theory and Practice of Size Exclusion Chromatography for the Analysis of Protein Aggregates. J Pharm Biomed Anal. 2014;101:161–173.
4. Ricker RD, Sandoval LA. Fast, Reproducible Size‐Exclusion Chromatography of Biological Macromolecules. J Chromatogr A. 1996;743:43–50.
5. Kamberi M, Chung P, DeVas R, et al. Analysis of Non‐covalent Aggregation of Synthetic hPTH (1–34) by Size‐Exclusion Chromatography and the Importance of Suppression of Non‐specific Interactions for a Precise Quantitation. J Chromatogr B. 2004;810:151–155.
6. Striegel AM, Yau WW, Kirkland JJ, Bly DD. Modern Size Exclusion Liquid Chromatography. Hoboken, NJ: John Wiley & Sons; 2009.
7. Cold Spring Harbor Laboratory Press. Phosphate Buffered Saline (PBS), Recipe. 2006.